Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
AssigneesGenentech, Inc., Hoffmann-La Roche Inc.
InventorsHideki Garren, Edmond Huatung Teng, Aurelien Viaccoz, Hans-Christian Von Buedingen
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
Claims17
A method of treating relapsing multiple sclerosis (RMS) in a subject in need thereof, comprising administering to the subject about 200 mg fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
A method of reducing the Annualized Relapse Rate (ARR) in a subject with RMS in need thereof, the method comprising administering to the subject about 200 mg fenebrutinib twice per day, or an equivalent amount of a pharmaceutically acceptable salt thereof.
A method of:
- increasing time to onset of composite 12-week disability progression (cCDP12) in a subject with RMS in need thereof;
- or
- increasing time to onset of 12-week confirmed disability progression (CDP12) in a subject with RMS in need thereof, or
- reducing the risk of experiencing cCDP12 in a subject with RMS in need thereof;
- or
- increasing time to onset of composite 24-week confirmed disability progression (cCDP24) in a subject with RMS in need thereof;
- or
- increasing time to onset of 24-week confirmed disability progression (CDP24) in a subject with RMS in need thereof;
- or
- reducing the risk of experiencing cCDP24 in a subject with RMS in need thereof;
- each method of comprising administering to the subject about 200 mg fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.